Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Shanshan Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0689-8774; OpenAlex author ID A5033709305. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 12

  1. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  2. Tumor-associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study. First author DOI 10.1002/mco2.183↗
  3. Investigation of the potential role of TGR5 in pancreatic cancer by a comprehensive molecular experiments and the liquid chromatography mass spectrometry (LC-M… Co-author DOI 10.1007/s12672-022-00504-2↗
  4. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12325-021-01819-2↗
  5. An iodine-125 seed strand combined with a metal stent versus a metal stent alone for obstructive jaundice caused by pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.brachy.2020.10.004↗
  6. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. Co-author DOI 10.1177/1758835920953728↗
  7. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. First author DOI 10.1016/j.canlet.2019.06.013↗
  8. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.21037/atm.2019.10.91↗
  9. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.2217/fon-2019-0264↗
  10. Lactic dehydrogenase to albumin ratio in prediction of unresectable pancreatic cancer with intervention chemotherapy. Co-author DOI 10.2217/fon-2017-0556↗
  11. Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes. Co-author DOI 10.5114/ceji.2018.77381↗
  12. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. First author DOI 10.7150/jca.20917↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ning Pu · 10 shared papers, 2017–2025 · strength 1.06
  2. Qiangda Chen · 5 shared papers, 2019–2025 · strength 0.63
  3. Hanlin Yin · 5 shared papers, 2019–2025 · strength 0.62
  4. Wenchuan Wu · 6 shared papers, 2017–2022 · strength 0.57
  5. Jun Yu · 5 shared papers, 2019–2022 · strength 0.53
  6. Wenhui Lou · 4 shared papers, 2018–2025 · strength 0.47
  7. Joseph R. Habib · 3 shared papers, 2019–2025 · strength 0.39
  8. Wenhui Lou · 4 shared papers, 2017–2022 · strength 0.38
  9. Sami Shoucair · 2 shared papers, 2022–2025 · strength 0.34
  10. Xiaolin Wang · 3 shared papers, 2017–2022 · strength 0.30
  11. Yi Chen · 2 shared papers, 2020–2021 · strength 0.21
  12. Minjie Yang · 2 shared papers, 2020–2021 · strength 0.21
  13. Xiaolin Wang · 2 shared papers, 2018–2021 · strength 0.19
  14. Junhao Li · 2 shared papers, 2018–2021 · strength 0.19
  15. Chenye Shi · 1 shared paper, 2025 · strength 0.19
  16. Liang Liu · 1 shared paper, 2025 · strength 0.19
  17. Huaxiang Xu · 1 shared paper, 2025 · strength 0.19
  18. Lei Zhang · 1 shared paper, 2025 · strength 0.19
  19. Taochen He · 1 shared paper, 2025 · strength 0.19
  20. Michael Goggins · 1 shared paper, 2025 · strength 0.19
  21. Yun Jin · 1 shared paper, 2025 · strength 0.19
  22. Lingdi Yin · 2 shared papers, 2019 · strength 0.18
  23. Yayun Zhu · 2 shared papers, 2019 · strength 0.18
  24. Hai‐Jie Hu · 2 shared papers, 2019 · strength 0.18
  25. Guofeng Zhou · 2 shared papers, 2018–2020 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.